BMC Women's Health · Aug 25, 2026
The effects of different types of hormonal contraception on bone mineral density in women of reproductive age: a systematic review and meta-analysis
By Sulaimani M, Bamagaus HY, Addas MA et al.
BACKGROUND: Approximately 150 million women worldwide use hormonal contraceptives; however, formulation-specific effects on bone mineral density (BMD) during the reproductive years remain poorly characterized. Prior meta-analyses are limited by the absence of untreated control groups and inadequate heterogeneity quantification, leaving clinicians without reliable guidance. OBJECTIVES: To determine the effect of hormonal contraceptives on lumbar spine and femoral neck bone mineral density (BMD) in reproductive-aged women relative to untreated non-user controls stratified by contraceptive category, progestin class, and ethinylestradiol (EE) dose. METHODS: This was a pre-registered systematic review and meta-analysis (PROSPERO: CRD420250640432; PRISMA, 2020). The MEDLINE, Embase, Web of Science, and Cochrane CENTRAL of Controlled Trials databases were searched from inception to December 2024. Eligible studies required a mandatory untreated control arm and ≥ 12-month DXA follow-up in women of reproductive age. Effect sizes were pooled as weighted mean differences (WMD) using the DerSimonian-Laird random-effects model. Evidence certainly was rated using GRADE. RESULTS: Seven studies (k = 15 comparisons; n = 1,488 completers) met all inclusion criteria. The pooled WMD for lumbar spine BMD at 12 months was - 0.003 g/cm² (95% CI: -0.010 to + 0.005; p = 0.470; I² = 38.7%), below DXA precision limits and representing less than 0.3% of mean baseline BMD. COC users showed no significant BMD difference from controls across all progestin classes (WMD = - 0.0004 g/cm²; p = 0.925). A clinically interpretable EE-dose gradient emerged: low-dose formulations (≤ 20 µg; k = 8) showed a small but significant homogeneous reduction (WMD = - 0.011 g/cm²; 95% CI: -0.016 to - 0.005; p < 0.001; I² = 0%), while standard-dose formulations (30-35 µg) did not (WMD = + 0.009 g/cm²; p = 0.193). DMPA demonstrated a significant 2.0% lumbar spine BMD reduction (WMD = - 0.020 g/cm²; 95% CI: -0.038 to - 0.002; p = 0.030). RCT-only sensitivity analysis (k = 10) yielded WMD = - 0.006 g/cm² (p = 0.002; I² = 0%). The GRADE certainty was moderate. CONCLUSIONS: COCs do not materially alter BMD over 12 months in reproductive-age women, with consistent null effects across all progestin classes. A biologically plausible EE dose gradient was identified; DMPA use warrants individualized counselling given clinically relevant, though reversible, bone loss. Adequately powered long-term randomized trials targeting low-dose formulations, adolescents, and DMPA continuers are urgently needed.
doi.org/10.1186/s12905-026-04802-7Open accessPubMed 43052958Interventions